Duramed and estrogens
FDA refuses generic firm's request for an indefinite extension of the June 15 deadline for replies to the agency's proposed withdrawal of all ANDAs for generic conjugated estrogens on June 12. Duramed had sought the extension in a June 4 petition in which it alleged that FDA's May 4 ad hoc subcommittee on conjugated estrogens meeting was prejudiced by several panel members with conflicts of interest.
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”